nach oben

Alzheimer's Research & Therapy

Erschienen in:

01.06.2012 | Review

Ayurvedic medicinal plants for Alzheimer's disease: a review

verfasst von: Rammohan V Rao, Olivier Descamps, Varghese John, Dale E Bredesen

Erschienen in: Alzheimer's Research & Therapy | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Alzheimer's disease is an age-associated, irreversible, progressive neurodegenerative disease that is characterized by severe memory loss, unusual behavior, personality changes, and a decline in cognitive function. No cure for Alzheimer's exists, and the drugs currently available to treat the disease have limited effectiveness. It is believed that therapeutic intervention that could postpone the onset or progression of Alzheimer's disease would dramatically reduce the number of cases in the next 50 years. Ayurvedic medicinal plants have been the single most productive source of leads for the development of drugs, and over a hundred new products are already in clinical development. Indeed, several scientific studies have described the use of various Ayurvedic medicinal plants and their constituents for treatment of Alzheimer's disease. Although the exact mechanism of their action is still not clear, phytochemical studies of the different parts of the plants have shown the presence of many valuable compounds, such as lignans, flavonoids, tannins, polyphenols, triterpenes, sterols, and alkaloids, that show a wide spectrum of pharmacological activities, including anti-inflammatory, anti-amyloidogenic, anti-cholinesterase, hypolipidemic, and antioxidant effects. This review gathers research on various medicinal plants that have shown promise in reversing the Alzheimer's disease pathology. The report summarizes information concerning the phytochemistry, biological, and cellular activities and clinical applications of these various plants in order to provide sufficient baseline information that could be used in drug discovery campaigns and development process, thereby providing new functional leads for Alzheimer's disease.

Alzheimer's Association: 2010 Alzheimer's disease facts and figures. Alzheimers Dement. 6: 158-194.

Bredesen DE: Neurodegeneration in Alzheimer's disease: caspases and synaptic element interdependence. Mol Neurodegener. 2009, 4: 27-10.1186/1750-1326-4-27.PubMedCentralPubMed

Abascal K, Yarnell E: Alzheimer's disease: part 2--A botanical treatment plan. Alternative and Complementary Therapies. 2004, 10: 67-72.

Perry EK, Pickering AT, Wang WW, Houghton PJ, Perry NS: Medicinal plants and Alzheimer's disease: from ethnobotany to phytotherapy. J Pharm Pharmacol. 1999, 51: 527-534.PubMed

Howes MJ, Perry NS, Houghton PJ: Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytother Res. 2003, 17: 1-18. 10.1002/ptr.1280.PubMed

Kennedy DO, Wightman EL: Herbal extracts and phytochemicals: plant secondary metabolites and the enhancement of human brain function. Adv Nutr. 2011, 2: 32-50.PubMedCentralPubMed

Kumar V: Potential medicinal plants for CNS disorders: an overview. Phytother Res. 2006, 20: 1023-1035. 10.1002/ptr.1970.PubMed

Manyam BV: Dementia in Ayurveda. J Altern Complement Med. 1999, 5: 81-88. 10.1089/acm.1999.5.81.PubMed

Mishra LC, Singh BB, Dagenais S: Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev. 2000, 5: 334-346.PubMed

10.

Kelley BJ, Knopman DS: Alternative medicine and Alzheimer disease. Neurologist. 2008, 14: 299-306. 10.1097/NRL.0b013e318172cf4d.PubMedCentralPubMed

11.

Wollen KA: Alzheimer's disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners. Altern Med Rev. 2010, 15: 223-244.PubMed

12.

Russo A, Izzo AA, Cardile V, Borrelli F, Vanella A: Indian medicinal plants as antiradicals and DNA cleavage protectors. Phytomedicine. 2001, 8: 125-132. 10.1078/0944-7113-00021.PubMed

13.

Monograph. Withania somnifera. Altern Med Rev. 2004, 9: 211-214.

14.

Auddy B, Hazra J, Mitra A, Abedon B, Ghosal S: A standardized Withania somnifera extract significantly reduces stress-related parameters in chronically stressed humans: a double-blind randomized, placebo-controlled study. J Am Nutra Assoc. 2008, 11: 50-56.

15.

Matsuda H, Murakami T, Kishi A, Yoshikawa M: Structures of withanosides I, II, III, IV, V, VI, and VII, new withanolide glycosides, from the roots of Indian Withania somnifera DUNAL. and inhibitory activity for tachyphylaxis to clonidine in isolated guinea-pig ileum. Bioorg Med Chem. 2001, 9: 1499-1507. 10.1016/S0968-0896(01)00024-4.PubMed

16.

Dhuley JN: Effect of ashwagandha on lipid peroxidation in stress-induced animals. J Ethnopharmacol. 1998, 60: 173-178. 10.1016/S0378-8741(97)00151-7.PubMed

17.

Jayaprakasam B, Padmanabhan K, Nair MG: Withanamides in Withania somnifera fruit protect PC-12 cells from beta-amyloid responsible for Alzheimer's disease. Phytother Res. 2010, 24: 859-863.PubMed

18.

Parihar MS, Hemnani T: Phenolic antioxidants attenuate hippocampal neuronal cell damage against kainic acid induced excitotoxicity. J Biosci. 2003, 28: 121-128. 10.1007/BF02970142.PubMed

19.

Kumar S, Harris RJ, Seal CJ, Okello EJ: An aqueous extract of Withania somnifera root inhibits amyloid beta fibril formation in vitro. Phytother Res. 2012, 26: 113-117. 10.1002/ptr.3512.PubMed

20.

Tohda C, Kuboyama T, Komatsu K: Search for natural products related to regeneration of the neuronal network. Neurosignals. 2005, 14: 34-45. 10.1159/000085384.PubMed

21.

Kuboyama T, Tohda C, Zhao J, Nakamura N, Hattori M, Komatsu K: Axon- or dendrite-predominant outgrowth induced by constituents from Ashwagandha. Neuroreport. 2002, 13: 1715-1720. 10.1097/00001756-200210070-00005.PubMed

22.

Schliebs R, Liebmann A, Bhattacharya SK, Kumar A, Ghosal S, Bigl V: Systemic administration of defined extracts from Withania somnifera (Indian Ginseng) and Shilajit differentially affects cholinergic but not glutamatergic and GABAergic markers in rat brain. Neurochem Int. 1997, 30: 181-190. 10.1016/S0197-0186(96)00025-3.PubMed

23.

Tohda C, Kuboyama T, Komatsu K: Dendrite extension by methanol extract of Ashwagandha (roots of Withania somnifera) in SK-N-SH cells. Neuroreport. 2000, 11: 1981-1985. 10.1097/00001756-200006260-00035.PubMed

24.

Kuboyama T, Tohda C, Komatsu K: Neuritic regeneration and synaptic reconstruction induced by withanolide A. Br J Pharmacol. 2005, 144: 961-971. 10.1038/sj.bjp.0706122.PubMedCentralPubMed

25.

Aggarwal BB, Sundaram C, Malani N, Ichikawa H: Curcumin: the Indian solid gold. Adv Exp Med Biol. 2007, 595: 1-75. 10.1007/978-0-387-46401-5_1.PubMed

26.

Shishodia S, Sethi G, Aggarwal BB: Curcumin: getting back to the roots. Ann N Y Acad Sci. 2005, 1056: 206-217. 10.1196/annals.1352.010.PubMed

27.

Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, Rock CL, Pruitt MA, Yang F, Hudspeth B, Hu S, Faull KF, Teter B, Cole GM, Frautschy SA: Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther. 2008, 326: 196-208. 10.1124/jpet.108.137455.PubMedCentralPubMed

28.

Chainani-Wu N: Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med. 2003, 9: 161-168. 10.1089/107555303321223035.PubMed

29.

Ganguli M, Chandra V, Kamboh MI, Johnston JM, Dodge HH, Thelma BK, Juyal RC, Pandav R, Belle SH, DeKosky ST: Apolipoprotein E polymorphism and Alzheimer disease: The Indo-US Cross-National Dementia Study. Arch Neurol. 2000, 57: 824-830. 10.1001/archneur.57.6.824.PubMed

30.

Breitner JC, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, Pericak-Vance MA, Saunders AM: Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging. 1995, 16: 523-530. 10.1016/0197-4580(95)00049-K.PubMed

31.

Cole GM, Lim GP, Yang F, Teter B, Begum A, Ma Q, Harris-White ME, Frautschy SA: Prevention of Alzheimer's disease: omega-3 fatty acid and phenolic anti-oxidant interventions. Neurobiol Aging. 2005, 26 (Suppl 1): 133-136.PubMed

32.

Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM: The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001, 21: 8370-8377.PubMed

33.

Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM: Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005, 280: 5892-5901.PubMed

34.

Butterfield D, Castegna A, Pocernich C, Drake J, Scapagnini G, Calabrese V: Nutritional approaches to combat oxidative stress in Alzheimer's disease. J Nutr Biochem. 2002, 13: 444-10.1016/S0955-2863(02)00205-X.PubMed

35.

National Toxicology Program: NTP Toxicology and Carcinogenesis Studies of Turmeric Oleoresin (CAS No. 8024-37-1) (Major Component 79%-85% Curcumin, CAS No. 458-37-7) in F344/N Rats and B6C3F1 Mice (Feed Studies). Natl Toxicol Program Tech Rep Ser. 1993, 427: 1-275.

36.

ClinicalTrials.gov homepage. [http://clinicaltrials.gov/]

37.

Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, Lam L, Leung V, Hui E, Ng C, Woo J, Chiu HF, Goggins WB, Zee BC, Cheng KF, Fong CY, Wong A, Mok H, Chow MS, Ho PC, Ip SP, Ho CS, Yu XW, Lai CY, Chan MH, Szeto S, Chan IH, Mok V: Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol. 2008, 28: 110-113. 10.1097/jcp.0b013e318160862c.PubMed

38.

Belkacemi A, Doggui S, Dao L, Ramassamy C: Challenges associated with curcumin therapy in Alzheimer disease. Expert Rev Mol Med. 2011, 13: e34-PubMed

39.

Bacopa monniera. Monograph. Altern Med Rev. 2004, 9: 79-85.

40.

Russo A, Borrelli F: Bacopa monniera, a reputed nootropic plant: an overview. Phytomedicine. 2005, 12: 305-317. 10.1016/j.phymed.2003.12.008.PubMed

41.

Dhanasekaran M, Tharakan B, Holcomb LA, Hitt AR, Young KA, Manyam BV: Neuroprotective mechanisms of ayurvedic antidementia botanical Bacopa monniera. Phytother Res. 2007, 21: 965-969. 10.1002/ptr.2195.PubMed

42.

Stough C, Downey LA, Lloyd J, Silber B, Redman S, Hutchison C, Wesnes K, Nathan PJ: Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial. Phytother Res. 2008, 22: 1629-1634. 10.1002/ptr.2537.PubMed

43.

Singh RH, Narsimhamurthy K, Singh G: Neuronutrient impact of Ayurvedic Rasayana therapy in brain aging. Biogerontology. 2008, 9: 369-374. 10.1007/s10522-008-9185-z.PubMed

44.

Shinomol GK, Bharath MM: Exploring the role of 'Brahmi' (Bocopa monnieri and Centella asiatica) in brain function and therapy. Recent Pat Endocr Metab Immune Drug Discov. 2011, 5: 33-49. 10.2174/187221411794351833.PubMed

45.

Singh HK, Dhawan BN: Effect of Bacopa monniera Linn. (brahmi) extract on avoidance responses in rat. J Ethnopharmacol. 1982, 5: 205-214. 10.1016/0378-8741(82)90044-7.PubMed

46.

Uabundit N, Wattanathorn J, Mucimapura S, Ingkaninan K: Cognitive enhancement and neuroprotective effects of Bacopa monnieri in Alzheimer's disease model. J Ethnopharmacol. 2010, 127: 26-31. 10.1016/j.jep.2009.09.056.PubMed

47.

Bhattacharya SK, Bhattacharya A, Kumar A, Ghosal S: Antioxidant activity of Bacopa monniera in rat frontal cortex, striatum and hippocampus. Phytother Res. 2000, 14: 174-179. 10.1002/(SICI)1099-1573(200005)14:3<174::AID-PTR624>3.0.CO;2-O.PubMed

48.

Limpeanchob N, Jaipan S, Rattanakaruna S, Phrompittayarat W, Ingkaninan K: Neuroprotective effect of Bacopa monnieri on beta-amyloid-induced cell death in primary cortical culture. J Ethnopharmacol. 2008, 120: 112-117. 10.1016/j.jep.2008.07.039.PubMed

49.

Pravina K, Ravindra KR, Goudar KS, Vinod DR, Joshua AJ, Wasim P, Venkateshwarlu K, Saxena VS, Amit A: Safety evaluation of BacoMind in healthy volunteers: a phase I study. Phytomedicine. 2007, 14: 301-308. 10.1016/j.phymed.2007.03.010.PubMed

50.

Roodenrys S, Booth D, Bulzomi S, Phipps A, Micallef C, Smoker J: Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacology. 2002, 27: 279-281. 10.1016/S0893-133X(01)00419-5.PubMed

51.

Nathan PJ, Clarke J, Lloyd J, Hutchison CW, Downey L, Stough C: The acute effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy normal subjects. Hum Psychopharmacol. 2001, 16: 345-351. 10.1002/hup.306.PubMed

52.

Stough C, Lloyd J, Clarke J, Downey LA, Hutchison CW, Rodgers T, Nathan PJ: The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology (Berl). 2001, 156: 481-484. 10.1007/s002130100815.

53.

Shukia B, Khanna NK, Godhwani JL: Effect of Brahmi Rasayan on the central nervous system. J Ethnopharmacol. 1987, 21: 65-74. 10.1016/0378-8741(87)90095-X.PubMed

54.

Bihaqi SW, Sharma M, Singh AP, Tiwari M: Neuroprotective role of Convolvulus pluricaulis on aluminium induced neurotoxicity in rat brain. J Ethnopharmacol. 2009, 124: 409-415. 10.1016/j.jep.2009.05.038.PubMed

55.

Malik J, Karan M, Vasisht K: Nootropic, anxiolytic and CNS-depressant studies on different plant sources of shankhpushpi. Pharm Biol. 2011, 49: 1234-1242. 10.3109/13880209.2011.584539.PubMed

56.

Mukherjee PK, Kumar V, Kumar NS, Heinrich M: The Ayurvedic medicine Clitoria ternatea--from traditional use to scientific assessment. J Ethnopharmacol. 2008, 120: 291-301. 10.1016/j.jep.2008.09.009.PubMed

57.

Jain NN, Ohal CC, Shroff SK, Bhutada RH, Somani RS, Kasture VS, Kasture SB: Clitoria ternatea and the CNS. Pharmacol Biochem Behav. 2003, 75: 529-536. 10.1016/S0091-3057(03)00130-8.PubMed

58.

Sethiya NK, Nahata A, Mishra SH, Dixit VK: An update on Shankhpushpi, a cognition-boosting Ayurvedic medicine. Zhong Xi Yi Jie He Xue Bao. 2009, 7: 1001-1022. 10.3736/jcim20091101.PubMed

59.

Nahata A, Patil UK, Dixit VK: Effect of Convulvulus pluricaulis Choisy. on learning behaviour and memory enhancement activity in rodents. Nat Prod Res. 2008, 22: 1472-1482. 10.1080/14786410802214199.PubMed

60.

Nahata A, Patil UK, Dixit VK: Effect of Evolvulus alsinoides Linn. on learning behavior and memory enhancement activity in rodents. Phytother Res. 2010, 24: 486-493.PubMed

61.

Sharma K, Bhatnagar M, Kulkarni SK: Effect of Convolvulus pluricaulis Choisy and Asparagus racemosus Willd on learning and memory in young and old mice: a comparative evaluation. Indian J Exp Biol. 2010, 48: 479-485.PubMed

62.

Rai KS, Murthy KD, Karanth KS, Nalini K, Rao MS, Srinivasan KK: Clitoria ternatea root extract enhances acetylcholine content in rat hippocampus. Fitoterapia. 2002, 73: 685-689. 10.1016/S0367-326X(02)00249-6.PubMed

63.

Rai KS, Murthy KD, Karanth KS, Rao MS: Clitoria ternatea (Linn) root extract treatment during growth spurt period enhances learning and memory in rats. Indian J Physiol Pharmacol. 2001, 45: 305-313.PubMed

64.

Taranalli AD, Cheeramkuzhy TC: Influence of Clitoria ternatea extracts on memory and central cholinergic activity in rats. Pharm Biol. 2000, 38: 51-56.PubMed

65.

Rai KS, Murthy KD, Rao MS, Karanth KS: Altered dendritic arborization of amygdala neurons in young adult rats orally intubated with Clitorea ternatea aqueous root extract. Phytother Res. 2005, 19: 592-598. 10.1002/ptr.1657.PubMed

66.

Cervenka F, Jahodar L: [Plant metabolites as nootropics and cognitives]. Ceska Slov Farm. 2006, 55: 219-229. Article in CzechPubMed

67.

Dhanasekaran M, Holcomb LA, Hitt AR, Tharakan B, Porter JW, Young KA, Manyam BV: Centella asiatica extract selectively decreases amyloid beta levels in hippocampus of Alzheimer's disease animal model. Phytother Res. 2009, 23: 14-19. 10.1002/ptr.2405.PubMed

68.

da Rocha MD, Viegas FP, Campos HC, Nicastro PC, Fossaluzza PC, Fraga CA, Barreiro EJ, Viegas C: The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: Alzheimer's disease. CNS Neurol Disord Drug Targets. 2011, 10: 251-270.PubMed

69.

Veerendra Kumar MH, Gupta YK: Effect of Centella asiatica on cognition and oxidative stress in an intracerebroventricular streptozotocin model of Alzheimer's disease in rats. Clin Exp Pharmacol Physiol. 2003, 30: 336-342. 10.1046/j.1440-1681.2003.03842.x.PubMed

70.

Xu Y, Cao Z, Khan I, Luo Y: Gotu Kola (Centella asiatica) extract enhances phosphorylation of cyclic AMP response element binding protein in neuroblastoma cells expressing amyloid beta peptide. J Alzheimers Dis. 2008, 13: 341-349.PubMed

71.

Bhanumathy M, Harish MS, Shivaprasad HN, Sushma G: Nootropic activity of Celastrus paniculatus seed. Pharm Biol. 2010, 48: 324-327. 10.3109/13880200903127391.PubMed

72.

Godkar P, Gordon RK, Ravindran A, Doctor BP: Celastrus paniculatus seed water soluble extracts protect cultured rat forebrain neuronal cells from hydrogen peroxide-induced oxidative injury. Fitoterapia. 2003, 74: 658-669. 10.1016/S0367-326X(03)00190-4.PubMed

73.

Godkar PB, Gordon RK, Ravindran A, Doctor BP: Celastrus paniculatus seed water soluble extracts protect against glutamate toxicity in neuronal cultures from rat forebrain. J Ethnopharmacol. 2004, 93: 213-219. 10.1016/j.jep.2004.03.051.PubMed

74.

Godkar PB, Gordon RK, Ravindran A, Doctor BP: Celastrus paniculatus seed oil and organic extracts attenuate hydrogen peroxide- and glutamate-induced injury in embryonic rat forebrain neuronal cells. Phytomedicine. 2006, 13: 29-36. 10.1016/j.phymed.2003.11.011.PubMed

75.

Kumar MH, Gupta YK: Antioxidant property of Celastrus paniculatus willd.: a possible mechanism in enhancing cognition. Phytomedicine. 2002, 9: 302-311. 10.1078/0944-7113-00136.PubMed

76.

Chatterjee A, Basak B, Saha M, Dutta U, Mukhopadhyay C, Banerji J, Konda Y, Harigaya Y: Structure and stereochemistry of nardostachysin, a new terpenoid ester constituent of the rhizomes of Nardostachys jatamansi. J Nat Prod. 2000, 63: 1531-1533. 10.1021/np990503m.PubMed

77.

Bagchi A, Oshima Y, Hikino H: Jatamols A and B: Sesquiterpenoids of Nardostachys jatamansi Roots1. Planta Med. 1991, 57: 282-283. 10.1055/s-2006-960091.PubMed

78.

Bagchi A, Oshima Y, Hikino H: Neolignans and Lignans of Nardostachys jatamansi Roots1. Planta Med. 1991, 57: 96-97. 10.1055/s-2006-960037.PubMed

79.

Lyle N, Gomes A, Sur T, Munshi S, Paul S, Chatterjee S, Bhattacharyya D: The role of antioxidant properties of Nardostachys jatamansi in alleviation of the symptoms of the chronic fatigue syndrome. Behav Brain Res. 2009, 202: 285-290. 10.1016/j.bbr.2009.04.005.PubMed

80.

Joshi H, Parle M: Nardostachys jatamansi improves learning and memory in mice. J Med Food. 2006, 9: 113-118. 10.1089/jmf.2006.9.113.PubMed

81.

Das Gupta R: A new hypolipidaemic agent (gugulipid). J Assoc Physicians India. 1990, 38: 186-PubMed

82.

Gupta RD: Gugulipid: pro-lipaemic effect. J Assoc Physicians India. 1990, 38: 598-PubMed

83.

Urizar NL, Moore DD: GUGULIPID: a natural cholesterol-lowering agent. Annu Rev Nutr. 2003, 23: 303-313. 10.1146/annurev.nutr.23.011702.073102.PubMed

84.

Perluigi M, Joshi G, Sultana R, Calabrese V, De Marco C, Coccia R, Cini C, Butterfield DA: In vivo protective effects of ferulic acid ethyl ester against amyloid-beta peptide 1-42-induced oxidative stress. J Neurosci Res. 2006, 84: 418-426. 10.1002/jnr.20879.PubMed

85.

Scapagnini G, Butterfield DA, Colombrita C, Sultana R, Pascale A, Calabrese V: Ethyl ferulate, a lipophilic polyphenol, induces HO-1 and protects rat neurons against oxidative stress. Antioxid Redox Signal. 2004, 6: 811-818.PubMed

86.

Sultana R, Ravagna A, Mohmmad-Abdul H, Calabrese V, Butterfield DA: Ferulic acid ethyl ester protects neurons against amyloid beta- peptide(1-42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity. J Neurochem. 2005, 92: 749-758. 10.1111/j.1471-4159.2004.02899.x.PubMed

87.

Cui J, Huang L, Zhao A, Lew JL, Yu J, Sahoo S, Meinke PT, Royo I, Pelaez F, Wright SD: Guggulsterone is a farnesoid × receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J Biol Chem. 2003, 278: 10214-10220. 10.1074/jbc.M209323200.PubMed

88.

Saxena G, Singh SP, Pal R, Singh S, Pratap R, Nath C: Gugulipid, an extract of Commiphora whighitii with lipid-lowering properties, has protective effects against streptozotocin-induced memory deficits in mice. Pharmacol Biochem Behav. 2007, 86: 797-805. 10.1016/j.pbb.2007.03.010.PubMed

89.

Szapary PO, Wolfe ML, Bloedon LT, Cucchiara AJ, DerMarderosian AH, Cirigliano MD, Rader DJ: Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA. 2003, 290: 765-772. 10.1001/jama.290.6.765.PubMed

90.

Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD: A natural product that lowers cholesterol as an antagonist ligand for FXR. Science. 2002, 296: 1703-1706. 10.1126/science.1072891.PubMed

91.

Eckert GP, Wood WG, Muller WE: Statins: drugs for Alzheimer's disease?. J Neural Transm. 2005, 112: 1057-1071. 10.1007/s00702-004-0273-1.PubMed

92.

Kirsch C, Eckert GP, Koudinov AR, Muller WE: Brain cholesterol, statins and Alzheimer's disease. Pharmacopsychiatry. 2003, 36 (Suppl 2): S113-119.PubMed

93.

Vestergaard M, Hamada T, Morita M, Takagi M: Cholesterol, lipids, amyloid beta, and Alzheimer's. Curr Alzheimer Res. 2010, 7: 262-270. 10.2174/156720510791050821.PubMed

94.

Morley JE, Banks WA: Lipids and cognition. J Alzheimers Dis. 2010, 20: 737-747.PubMed

95.

Liu JP, Tang Y, Zhou S, Toh BH, McLean C, Li H: Cholesterol involvement in the pathogenesis of neurodegenerative diseases. Mol Cell Neurosci. 2010, 43: 33-42. 10.1016/j.mcn.2009.07.013.PubMed

96.

Harris JR, Milton NG: Cholesterol in Alzheimer's disease and other amyloidogenic disorders. Subcell Biochem. 2010, 51: 47-75. 10.1007/978-90-481-8622-8_2.PubMed

97.

Frawley D, Lad V: The Yoga of Herbs: An Ayurvedic Guide to Herbal Medicine. 1986, Twin Lakes, WI: Lotus Press

98.

Pires A, Fortuna A, Alves G, Falcao A: Intranasal drug delivery: how, why and what for?. J Pharm Pharm Sci. 2009, 12: 288-311.PubMed

99.

Turker S, Onur E, Ozer Y: Nasal route and drug delivery systems. Pharm World Sci. 2004, 26: 137-142.PubMed

100.

Illum L: Nasal drug delivery--possibilities, problems and solutions. J Control Release. 2003, 87: 187-198. 10.1016/S0168-3659(02)00363-2.PubMed

101.

Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B: Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012, 69: 29-38. 10.1001/archneurol.2011.233.PubMedCentralPubMed

102.

Dhuria SV, Hanson LR, Frey WH 2nd: Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2010, 99: 1654-1673.PubMed

103.

Rapaport MH, Schettler P, Bresee C: A preliminary study of the effects of a single session of Swedish massage on hypothalamic-pituitary-adrenal and immune function in normal individuals. J Altern Complement Med. 2010,

104.

Buckle J, Newberg A, Wintering N, Hutton E, Lido C, Farrar JT: Measurement of regional cerebral blood flow associated with the M technique-light massage therapy: a case series and longitudinal study using SPECT. J Altern Complement Med. 2008, 14: 903-910. 10.1089/acm.2007.0613.PubMed

105.

Keir ST: Effect of massage therapy on stress levels and quality of life in brain tumor patients--observations from a pilot study. Support Care Cancer. 2011, 19: 711-715. 10.1007/s00520-010-1032-5.PubMed

106.

Ouchi Y, Kanno T, Okada H, Yoshikawa E, Shinke T, Nagasawa S, Minoda K, Doi H: Changes in cerebral blood flow under the prone condition with and without massage. Neurosci Lett. 2006, 407: 131-135. 10.1016/j.neulet.2006.08.037.PubMed

107.

Pathirana W, Abhayawardhana P, Kariyawasam H, Ratnasooriya WD: Transcranial route of brain targeted delivery of methadone in oil. Indian J Pharm Sci. 2009, 71: 264-269. 10.4103/0250-474X.56024.PubMedCentralPubMed

108.

Saxena VS, Nadkarni VV: Nonpharmacological treatment of epilepsy. Ann Indian Acad Neurol. 2011, 14: 148-152. 10.4103/0972-2327.85870.PubMedCentralPubMed

109.

Uebaba K, Xu FH, Ogawa H, Tatsuse T, Wang BH, Hisajima T, Venkatraman S: Psychoneuroimmunologic effects of Ayurvedic oil-dripping treatment. J Altern Complement Med. 2008, 14: 1189-1198. 10.1089/acm.2008.0273.PubMed

110.

Xu F, Uebaba K, Ogawa H, Tatsuse T, Wang BH, Hisajima T, Venkatraman S: Pharmaco-physio-psychologic effect of Ayurvedic oil-dripping treatment using an essential oil from Lavendula angustifolia. J Altern Complement Med. 2008, 14: 947-956. 10.1089/acm.2008.0240.PubMed

111.

Mantle F: The role of alternative medicine in treating postnatal depression. Complement Ther Nurs Midwifery. 2002, 8: 197-203. 10.1054/ctnm.2002.0647.PubMed

112.

Jimbo D, Kimura Y, Taniguchi M, Inoue M, Urakami K: Effect of aromatherapy on patients with Alzheimer's disease. Psychogeriatrics. 2009, 9: 173-179. 10.1111/j.1479-8301.2009.00299.x.PubMed

113.

Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, Lyketsos CG: Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol. 2009, 5: 245-255. 10.1038/nrneurol.2009.39.PubMed

Titel: Ayurvedic medicinal plants for Alzheimer's disease: a review
verfasst von: Rammohan V Rao
Olivier Descamps
Varghese John
Dale E Bredesen
Publikationsdatum: 01.06.2012
Verlag: BioMed Central
Erschienen in: Alzheimer's Research & Therapy / Ausgabe 3/2012
Elektronische ISSN: 1758-9193
DOI: https://doi.org/10.1186/alzrt125

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains

Recent Alzheimer's disease research highlights

Long-term benefit from deep brain stimulation of the subthalamic nucleus: is it for everyone?

Phenotypic differences between apolipoprotein E genetic subgroups: research and clinical implications

Age-related increase in amyloid plaque burden is associated with impairment in conditioned fear memory in CRND8 mouse model of amyloidosis